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Abstract The National Institute of Mental Health in
cooperation with the National Institute on Drug Abuse and
the National Institute of Neurological Disorders and Stroke
organized a meeting on July 24–25, 2008 to develop novel
research directions for neuroAIDS research. The deliber-
ations of this meeting are outlined in this brief report.
Several critical research areas in neuroAIDS were identified
as areas of emphasis. Opportunities for collaborations
between large NIH-funded projects were also discussed.
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Introduction
A meeting was held to plan future strategies for Domestic
and International NeuroAIDS research in Bethesda, Mary-
land on July 24–25, 2008. This meeting was organized by
the National Institute of Mental Health (NIMH) with full
cooperation of the National Institute on Drug Abuse
(NIDA) and National Institute of Neurological Disorders
and Stroke (NINDS). The focus of the meeting was toward
developing novel research directions for domestic and
international neuroAIDS research. Introductions were made
by Dr. Ellen Stover (NIMH) who welcomed participants
J Neuroimmune Pharmacol (2009) 4:283–297
DOI 10.1007/s11481-009-9159-1
NeuroAIDS Research Participants. Cristian Achim, University of
California, San Diego, San Diego, CA; Sunil Ahuja, University of
Texas Health Science Center at San Antonio, San Antonio, TX; James
Becker, University of Pittsburgh Medical School, Pittsburgh, PA; Bruce
Brew, University of New South Wales, Sydney, Australia; Janice
Clements, Johns Hopkins University, Baltimore, MD; Ronald Ellis,
University of California, San Diego, San Diego, CA; Leon Epstein,
Northwestern University Feinberg School of Medicine, Chicago, IL;
Lynda Erinoff, National Institute on Drug Abuse, National Institutes of
Health, Bethesda, MD; Dana Gabuzda, Dana Farber Cancer Institute,
Harvard Medical School Boston, MA; Harris Gelbard, University of
Rochester Medical Center School of Medicine, Rochester, NY;
Benjamin Gelman, University of Texas Galveston, TX; David
Goldstein, Duke University, Durham, NC; Colin Hall, University of
North Carolina, Chapel Hill, NC; Rohan Hazra, National Institute of
Child Health and Human Development, National Institutes of Health,
Bethesda, MD; Robert Heaton, University of California, San Diego,
SanDiego,CA; RobinHuebner,Division ofAIDS,NationalInstitute of
Allergy and Infectious Diseases, National Institute of Health, Bethesda,
MD; Kamel Khalili, Temple University, Philadelphia, PA; Dennis
Kolson, University of Pennsylvania, Philadelphia PA; Diane Lawrence,
National Institute on Drug Abuse, National Institutes of Health,
Bethesda, MD; Scott Letendre, University of California, San Diego,
San Diego, CA; Thomas Marcotte, University of California, San Diego,
San Diego, CA; Michael McGrath, University of California, San
Francisco, San Francisco, CA; Susan Morgello, Mount Sinai Medical
Center, New York, NY; Avindra Nath, Johns Hopkins University,
Baltimore, MD; Vinayaka Prasad, Albert Einstein School of Medicine,
Bronx, NY; Richard Price, University of California, San Francisco, San
Francisco, CA; Lynn Pulliam, University of California, San Francisco,
San Francisco, CA; Dianne Rausch, HIV Pathogenesis,
Neuropsychiatry and Treatment Branch, Center for Mental Health
Research on AIDS, National Institute of Mental Health, National
Institutes of Health Bethesda, MD; Kevin Robertson, University of
NorthCarolinaatChapelHill,Chapel Hill,NC;NedSacktor,TheJohns
Hopkins University, Baltimore, MD; Gerald Sharp Division of AIDS,
NationalInstituteofAllergyandInfectiousDiseases,NationalInstitutes
of Health, Bethesda, MD; Elyse Singer, University of California, Los
Angeles, Los Angeles, CA; Stephen Spector, University of California,
San Diego, LaJolla, CA; Beth Stevens, Harvard Medical School,
Children’s Hospital, Kirby Neurobiology Center, Boston, MA; Mario
Stevenson, University of Massachusetts Medical Center, Worcester,
MA; Ellen Stover, National Institute of Mental Health, National
Institutes of Health, Bethesda, MD; Ronald Swanstrom, University of
North Carolina at Chapel Hill-Chapel Hill, NC; Victor Valcour,
University of California, San Francisco, San Francisco, CA; David
Volsky, Columbia University Medical Center, New York, NY; Brian
Wigdahl, Drexel University College of Medicine, Philadelphia, PA;
May Wong, National Institute of Neurological Disorders and Stroke,
National Institutes of Health, Bethesda, MD; Constantin Yiannoutsos,
Indiana University, Indianapolis, IN; Christine Zink, The Johns
Hopkins University, Baltimore, MDand announced the appointment of Dr. Richard Nakamura
as the new Director of the NIMH Intramural Research
Program and the promotion of Dr. Jeymohan Joseph to
Chief of the HIV Pathogenesis, Neuropsychiatry and
Treatment Branch at NIMH.
Twenty-three years after its first involvement in acquired
immunodeficiency virus (AIDS) research, NIMH now holds
a portfolio of 120 grants and two contracts in neuroAIDS
(as of July 2008). Despite the years and the numbers of
advancements in science and technologies, questions remain
andseveralarefundamentaltowhatitfaced23yearsago.Dr.
Stover noted the importance of cooperation and collabora-
tion between institutes including NIDA and NINDS that
cosponsored the present workshop. Dr. Robert Eisinger
(Office of AIDS Research [OAR]) explained its role in
strategic planning for the overall NIH research agenda and
budget on HIV/AIDS. The current priorities of this effort are
prevention and treatment. OAR welcomed the input and
recommendations of the neuroAIDS community. Dr. Lynda
Erinoff (NIDA) noted that her agency’s neuroAIDS portfolio
is under active development. NIDA is working hard with its
sister agencies and the research community to enhance its
presence in this area of research. Dr. May Wong (NINDS)
said her institute is also working to develop a stronger
research program in neuroAIDS, and she looks forward to a
fruitful discussion in the next 2 days.
Dr. Joseph (NIMH) greeted the participants and acknowl-
edged the help of NIMH’s sister agencies in organizing the
workshop. The goal of the workshop is to identify key
priorities in neuroAIDS research for the next few years with
particular emphasis on emerging topics in pathogenesis and
new directions for therapeutics. The current research portfolio
includes both investigator-initiated research and research
projects developed at the program level, such as the CNS
HIV Antiretroviral Therapy Effects Research (CHARTER)
Program. The workshop is building from ongoing domestic
and international research efforts. Discussions are aimed at
establishing priorities for neuroAIDS research for future
years.
Mechanisms of HIV-SIV neuropathogenesis: emerging
research areas
Dr. Janice Clements (Johns Hopkins University [JHU])
presented data that targeted the response to early, acute
lentiviral infection and subsequent control over the course
of central nervous system (CNS) disease. Ten years of
experiments using pigtailed macaques as a non-human
primate (NHP) model of human immunodeficiency virus
type one (HIV-1) infection, including serial sacrifice as
early as 4 days to trace the precise course of the disease,
showed animals that handle the infection better tend to have
a higher viral load during acute infection than animals that
go on to develop CNS disease. Mechanisms develop in the
CNS during the first 7 to 21 days that allow some subjects’
brains to deal with both acute and chronic infection more
effectively. Markers for subsequent CNS disease include
elevated levels of CCL2 in cerebrospinal fluid (CSF)
relative to plasma, as well as tumor necrosis factor alpha
(TNF-α) and interleukin-10 (IL-10) in brain tissue. Viral
loads in both CSF and plasma are higher in animals that
go on to develop CNS disease; but at present, we do not
know whether progression is due to the role of virus or
the result of inflammatory dysregulation. Researchers need
better markers of immune dysregulation and the Hopkins
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activated by HIV infection) and interferon beta (IFN-β),
which turns on over 100 genes and thus contributes to the
immune cascade. It appears that IFN-β inhibits viral
replication and can even induce dormancy, but only up to
a point; and if the brain loses control of the IFN-β response
(e.g., in response to viral RNA), the virus can begin
replicating again, causing a second wave of virus that
contributes to later disease.
Dr. Clements identified a number of strategic priorities
for the field, many of them related to either a better
understanding of past breakthroughs, as well as (or in place
of) a better understanding through multidisciplinary
approaches. Broader and more collaborative approaches
are required because of the unique immunological environ-
ment of the brain. NIH could encourage these approaches
through grants that span institutes. The field also recognizes
the current problems with neuroAIDS in the antiretroviral
therapy (ART) era and the subsequent research needs by
focusing on ways to protect the nervous system. The field
would benefit from further development and exploitation of
animal models, especially the macaque model of HIV
pathogenesis.
Other important research questions put forward in this
lecture included the interplay between innate and adaptive
immune responses in the brain as they affect the neuro-
pathogenesis of HIV-1 infection; the impact of ART on
disease; bioimaging and peripheral biomarkers as they affect
the tempo and progression of disease; adjunctive therapies
for neuroAIDS; and virologic and immune responses as they
affect the brain including immunosuppression, immune
exhaustion, and epigenetics of neuroAIDS.
Host genetic factors regulating HIV-CNS disease: new
research opportunities
Dr. Sunil Ahuja (University of Texas Health Science Center
at San Antonio) described a “nodal” model of HIV/acquired
immunodeficiency virus, one in which the broad phenotype
of “AIDS” reflects progression to specific AIDS-defining
illnesses such as HIV-associated dementia (HAD) or cancer.
Hence, in genetic epidemiologic studies, it will be important
to define strategies to differentiate which genes or genetic
pathwaysassociatespecificallywithHADversusotherAIDS-
defining diseases. Additionally, the real challenge is to find
genes that have a mechanistic connection with AIDS and not
just a correlative connection. Another hypothesis worth
considerationingeneticepidemiologicstudiesisthatcomplex
phenotypes are not unique entities, but in fact, are mosaics of
common disease-specific alleles and non-disease-specific
modifying alleles in the population influenced by a vast array
of environmental factors. The latter describes the premise of
the common variants/multiple disease hypothesis of common
complex genetic disorders, which has been well studied in
autoimmune diseases.
The following vignettes highlight these points. First,
chemoattraction of monocytes to the brain as well as
monocyte/microglial activation is thought to play a key
role in the pathogenesis of HAD. To examine this using a
genetic epidemiologic approach, Dr. Ahuja’s group exam-
ined a polymorphism in the gene encoding monocyte
chemoattractant protein-1 (MCP-1) which is a potent
monocyte chemoattractant; this polymorphism is strongly
associated with increased expression of MCP-1. Among
HIV-positive persons of European descent, this polymor-
phism in MCP-1 was associated with an increased risk of
both Mycobacterium avium complex (MAC) and HAD.
Second, polymorphisms in the apolipoprotein E (apoE)
gene are known to play a role in Alzheimer’s disease (AD).
On the basis of the common variants/multiple disease
hypothesis of common complex genetic disorders, it was
hypothesized that these polymorphisms may also influence
HAD. However, the results showed that the recombinant
protein of the APOE isoform that is associated with increased
AD risk (APOE3) is associated with increased HIV cell entry
in vitro and the ApoE3 genotype was associated with a
faster rate of progression to AIDS. But interestingly, an
association with HAD was not detected in the cohort
studied, which may in part relate to the younger subjects
studied.
Other studies were presented illustrating how genetic
studies can be used to evaluate mechanisms underlying
HIVpathogenesis.Forexample,delayedtypehypersensitivity
(DTH) skin test to the neoantigen keyhole limpet hemocyanin
was evaluated in HIV-negative subjects. CCR5 genotypes
associated with variable DTH responses, but interestingly,
those CCR5 genotypes that associated with decreased DTH
responses in HIV-negative subjects, predicted a faster rate of
disease progression in HIV-positive subjects. These data
suggested that CCR5 genotypes may influence HIV-AIDS
susceptibility by impacting on viral entry-independent
parameters, in addition to their well-described impact on
viral entry. Finally, studies were presented showing the
association of a genotype in Duffy antigen receptor for
chemokines (DARC) with HIV disease course and HAD;
interestingly, this genotype is African-specific and associat-
ed with resistance to malaria.
In response to questions, Dr. Ahuja posited that some
genetic variants might convey immune suppression, and
specific alleles may drive disease pathogenesis towards
specific AIDS-defining illnesses such as HAD. Some alleles
that play a beneficial role in immune depletion may not
necessarily have a beneficial effect during immune reconsti-
tution as was shown for some HLA alleles. In addition to
DARC, other G-protein-coupled receptors called decoy
J Neuroimmune Pharmacol (2009) 4:283–297 285receptors alsobindtochemokineswithout transducingsignals
into the cell (e.g., D6 receptor).
Novel genomic approaches to delineate host genetic
factors involved in susceptibility to HIV-associated
dementias
Dr. David Goldstein (Duke University) explained several,
newer approaches that broaden research pursuits for host
genetic factors beyond previously studied factors (e.g.,
apoE, CCR5, or sodium channels). His team has looked
more broadly at the entire genome. These approaches were
made possible by newer technology such as the Sentrix
Human-Hap550 Genotyping BeadChip, which can evaluate
555,000 single nucleotide polymorphisms (SNPs) simulta-
neously. Because some of the SNPs serve as proxies for
others, this effectively scans most of the genome and
provides greater power in association studies. This tech-
nology does a better job on the European genome than with
those who descend from Africa, but it provides a valuable
complement to the candidate approach and has already
turned up some surprises. Duke's Center for HIV/AIDS
Vaccine Immunology (CHAVI) is using the Hap550 to
analyze a 600-sample cohort of HIV-exposed European
and Australian patients in order to identify gene variants
that play a role in variation in viral set point and
progression to CD4
+ T cells of <350. Raw data suggest
that as many as 280 genes affect these endpoints, but two
of the strongest associations with viral set point have been
the HLA-B 5701 allele and a second SNP located near the
HLA-C gene, which together explain 15% of the variation
in set point during early infection. Time to HIV disease
progression is also associated with two different genes,
one of which (ZNRD1) encodes an RNA polymerase I
subunit. The large cohort for these analyses provides good
coverage, and the results show that the real benefit of
protective alleles can extend time to CD4 loss from 4 to
8 years. This would allow physicians to have a better idea
of prognosis, even at diagnosis. However, no such signals
have been discovered in African or African-American
populations.
The next study using this approach will be in hemophilia
patients who have been exposed to HIV, but are not yet
infected. In the future, it may be possible to use these
techniques to merge the study of HIV and dementia, two
genetically and biologically complex diseases that may,
nevertheless, have some common factors, as well as many
non-overlapping factors.
In response to questions, Dr. Goldstein said that cohort
size is a challenge, as can controlling for age, toxicity, and
other factors. Many of the 280 “hits” may turn out to be
false positives. He believes that next generation chips, in
combination with imputation techniques, can get at 80% of
the variation in African populations.
Viral genetics and HIV-CNS disease
Dr. Dana Gabuzda (Harvard Medical School) outlined the
importance of viral diversity seen within clades, with
regards to neurotropism, neuroinvasiveness, and neuro-
virulence. In these works, the hypothesis put forward is that
HIV enters the brain during acute infection but remains
dormant until the late stages of disease. During this latency,
the virus evolves and genetic variations are common in the
brain, which reflect founder diversities, selective adapta-
tions to CNS target cells, and immune selection pressure.
One HIV-1 gp120 Env variant, N283, gives the virus a
preference for cells expressing low levels of CD4, such as
macrophages. Sequencing has shown significantly higher
levels of the N283 Env variant in brain tissue, compared
with lymphoid tissue, and in patients with dementia
compared with those with no cognitive dysfunction. Further
studies have shown that the loss of an N-linked glycosyl-
ation site at position 386 in the HIV envelope V4 region is
also associated with dementia. Further study will be needed
to determine whether neurotropic variants evolve in the
brain and whether therapeutics targeting Env-CD4 inter-
actions will be beneficial in treating HIV-associated
neurological disorders.
Differences in neurotropism and neurovirulence can also
be seen between HIV-1 clades. In Uganda, for example,
subtype D is associated with increased risk of dementia
compared with subtype A. There are conflicting findings for
clades C and B, probably because of a lack of understanding
of the determinants of dementia. Dual-tropic R5X4 HIV-1
strains, which may evolve after infection, are also implicated
in dementia and may be more common than is widely
believed. But leaky gut, which elevates the level of plasma
lipopolysaccharide, has also been associated with cognitive
impairment, and the activation of monocytes may also play a
role in CNS infection and viral persistence.
Future studies should include how ART affects viral
neuropathogenesis; the relative contributions of viral
replication, immune activation, and drug toxicity for brain
disease; the impact of clade diversity on neurocognitive
impairment; the influence of co-infections, drug abuse,
malnutrition, and other confounders; clade-specific differ-
ence in drug resistance mutations; and therapies to prevent
or ameliorate infection of the nervous system and neuro-
cognitive disorders.
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current and future trends
Dr. Howard E. Gendelman [University of Nebraska
Medical Center (UNMC)] suggested that the field now
has validated parameters for ART, including when to
initiate, what drugs to use, how to monitor, when to switch
medicines, and what drugs to switch. Combinations of
drugs work better now and longer than seen previously, and
patients benefit demonstrably from the magnitude and
duration of viral suppression.
However, ART is very demanding for patients, and non-
adherence can lead to therapeutic failures. In addition, drug
resistance is a continuing problem. At present, there is a
need for improved drug delivery systems. There is also a
need for improved biomarkers to guide both diagnosis and
therapy, especially for virus-associated neurodegenerative
disorders. Such biomarkers might come from transcriptomics
(gene chips), proteomics, or metabolomics technologies
currently underway in his and other laboratories.
Also needed are adjunctive therapies that can better target,
support, or extend the impacts of antiretrovirals (ARV).
Particularly attractive would be nanotechnology approaches
to formulate and deliver therapeutic agents in nanoparticles.
Macrophage-based drug delivery is a promising new tech-
nique. Nanoformulated ART essentially manipulates the
immune system for therapeutic purposes by using circulating
monocytesasdrugcarriers.Theabilitiestomovedrugsinside
cells have advantages as a depot for ART and to improve
compliance as drugs can be released from cells for periods up
to weeks or longer. Testing has been done in humanized
mouse models where reconstitution with human stem cells
repopulates a deficient immune system. Such models permit
studies over months rather than days or weeks. Improved
imaging systems, which have evolved from magnetic
resonance and computed axial tomography, are being used
to track migration of monocyte–macrophages to the brain and
target the delivery of specific therapeutics. In response to
questions, Dr. Gendelman added that further breakthroughs are
needed to optimize nanoparticle uptake and to read the kinetics
of drug delivery across the blood–brain barrier.
The classical complement cascade mediates CNS
synapse elimination: potential relevance
to HIV-associated neurodegeneration
Dr. Beth Stevens (Harvard Medical School) discussed
several similarities in signaling between astrocytes and
neurons during neurodevelopment and neurodegenerative
disease. In a developing nervous system, immature astro-
cytes emit signals that encourage developmental plasticity
in the synaptic connections of retinal ganglion cell (RGC)
neurons. In the mature brain, astrocytes are silent and RGC
nerve connections have been “edited down” to a few unique
circuits. It now appears that neurodegenerative disease
reactivates the astrocytes, which then re-induce develop-
mental plasticity in neurons. Gene chip analysis shows that
astrocytes significantly (10- to 30-fold) upregulate the C1q
gene in RGC neurons; this same gene initiates the classical
complement cascade, whose role is to mediate the elimina-
tion of unwanted debris by opsonization (coating) or lysis.
Because C1q tends to localize at the synapses and is
developmentally regulated, it thus appears that the cascade
is “tagging” unwanted synapses for elimination in the
developing brain. This conclusion has been confirmed in a
study of C1q knockout mice, which have sustained defects
in synapse elimination. This leads to the hypothesis that, in
neurodegenerative disease, reactive astrocytes re-express the
signal that induces C1q in neurons, thereby activating the
complement cascade to “kill” synapses in the early stages of
disease. This hypothesis was tested in the DBA/2J mouse
model of human glaucoma, which showed that neurodegen-
eration was largely RGC-specific, reactive astrocytes are
increased in the optic nerve and retina, and C1q is
significantly upregulated at early stages of disease. A similar
upregulation of C1q has also been observed in AD and other
neurodegenerative disorders. These findings are relevant to
HAD because C1q is also upregulated in the early stages of
HAD; infact,HIV gp41directlyinteracts withC1qtoactivate
the cascade. Activated astrocytes and other glia are thought to
send neuroinflammatory signals, and each astrocyte may
touchasmanyas100synapses.Severalmechanisticquestions
remain.WhatisthesignalthatactivatesC1q?Whichsynapses
are targeted? How are the “tagged” synapses eliminated? Is
this elimination an activity-dependent process? Researchers
are tryingtodevelop aninvitromodel ofsynapse elimination,
which they believe to be a hypo-activity-dependent “punish-
ment signal.” In response to a question, Dr. Stevens said that
C1q would be a logical target for molecular intervention if a
mechanism could befound toblock the signalthatactivates it.
She added that all dementia are complex disorders and that
this is, necessarily, a simplistic approach.
Overview of current neuroAIDS research
Overview of findings from the CNS HIV-1 ART therapy
effects research (CHARTER) study
Dr. Igor Grant (University of California at San Diego
[UCSD]) presented findings from the ongoing CHARTER
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ART and neurologic disease in a cohort of 1,600 HIV-1
seropositive volunteers at six sites. A subset of 600 patients
will be followed longitudinally with 6-month follow-ups.
At intake, 71% of volunteers were using at least one ART,
with a median of three. Between 2003 and 2007, there
emerged several trends in therapy that have had a
substantive impact on care and are noteworthy. Drugs
containing dideoxynucleosides (D-drugs) declined by 63%;
boosting of protease inhibitors (PIs) increased by 40%;
overall use of non-nucleoside reverse transcriptase inhib-
itors (NNRTIs) declined by 24%, but Atripla increased to
17% of all regimens; and the proportion of regimens with
CNS penetration effectiveness (CPE) scores of ≥2.0
declined by 38% (increased CPE score is related to viral
suppression in CSF). In the CHARTER study, paired CSF
and blood samples were collected from 1,247 volunteers.
Of these, viral loads exceeded 50 copies/mL in 30% of CSF
samples and 52% of blood samples. CSF values exceeded
blood values in 4%, and less than 1% had detectable loads in
CSF, but none in the blood. However, neurocognitive
dysfunction is prevalent in the era of ART—about half of
the CHARTER volunteers have at least mild cognitive
impairment, and the types and degrees of this impairment
have changed little with changes in ART. Some neuropathol-
ogy may be due to co-morbid conditions, but these relation-
ships are complex (past or present drug use is associated with
less impairment, while being on ART is associated with more
impairment).
Brain neuroimaging studies showed that 34% of CHAR-
TER volunteers have significant abnormalities in white
matter, and MCP-1 (CCL2) emerges as a possible CSF
biomarker of white matter injury. White matter abnormal-
ities appear to be dynamic over time, but the volume of
abnormalities does not increase in all cases. Investigators
are seeking a better classification scheme for lesions.
Peripheral neuropathy also remains prevalent in CHARTER
volunteers with about 60% symptomatic. Neuropathy is
most common among older patients and current ART
recipients, especially those on D-drugs. Drug resistance is
a common factor in treatment failure and not all ART drugs
penetrate the CNS equally. CHARTER has confirmed
earlier findings of “compartmentalized” HIV populations
in the CNS and a high frequency of discordant drug
resistance patterns between CSF and plasma virus. In a sub-
study of 185 paired samples, 100 pairs had resistance
mutations in one or both compartments, and 39% of the
drug-resistant pairs demonstrated discordant resistance,
including 20 volunteers who were currently receiving
ART. In fact, current ARV was the strongest correlate of
discordant resistance, yet low CPE scores did not appear to
be a predictor. Significantly, discordant resistance was
positively associated with neurocognitive impairment.
Questionsarisingfrom thesefindings include thefollowing:
& What are the mechanisms for the persistence of
neurological disease despite ART compliance and
virologic control?
& What is the triggering event?
& How do host genetic factors interplay with viral factors,
therapeutics, and co-morbidities to increase the likeli-
hood of neurological disease?
& By what mechanism does discordant resistance relate to
neurocognitive impairment?
& How can biomarkers be used to detect and monitor
AIDS-related neurological disease?
NIMH-funded international NeuroAIDS efforts (R01
and R21): recent findings and challenges from studies
in China, India, Brazil, and Romania
Dr. Ron Ellis (UCSD) described research on the effects of
HIV clade and neurocognitive disorders in Curitiba, Brazil.
Whereas all known HIV clades, groups, and subtypes can
befoundinacentralAfrican sitelikeCameroon,Curitibahas
a patient population that is 64% clade B and 30% clade C,
making it a natural laboratory for comparing the impact
of clade on neurocognitive impairment. The specific aims
of this study were to (1) demonstrate the cross-cultural
applicability of a neurocognitive assessment that has already
been validated in the USA and (2) determine whether
neurocognitive impairment is more frequent or severe in
Brazilians infected with clade B versus clade C. Volunteers
are currently being enrolled in collaboration with the Federal
University of Parana and three community organizations in
Curitiba.
Dr. Scott Letendre (UCSD) reported on neuroAIDS
research in India, where the prevalence of HAD is officially
estimated at less than 6% but may be as high as 56% with
90% of patients expressing clade C. It is hypothesized that
a variation in clade C Tat may result in reduced migration
across the blood–brain barrier and that the lack of
variability in the V3 loop of clade C Env may make it
less neurotropic. The research is designed to determine the
prevalence and nature of HIV-1-associated neurological
disorders (HAND) in clade C volunteers in India, the
impact of ART on HAND and the influence of viral
genetics and host factors on the development of HAND in
individuals infected with clade C virus. Researchers will
follow 600 volunteers (300 HIV-1 seropositive and 300
controls) in Pune, Maharashtra through initial screening and
annual follow-ups; 60 volunteers have been enrolled to
date. Challenges include co-morbidities [tuberculosis (TB),
malaria, malnutrition], assessment values (illiteracy and
low, everyday function), and institutional disconnects that
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in northern and southeastern India.
Dr. Cristian Achim (UCSD) described neuroAIDS
research in Romania, which has a large population of
adolescents who were infected with clade F as infants. The
study will follow 75 volunteers (50 HIV-1 seropositive, 25
uninfected) to confirm the cross-cultural applicability of
their neurocognitive test battery, to identify co-morbidities
and to characterize the neurotropism of clade F. Preliminary
findings indicate that these volunteers face a range of social
and medical challenges, with co-morbidities that include
hepatitis B and C (HBV, HCV), TB, sub-acute measles and
encephalitis. Early samples show a high level of virus in
CSF compared with blood, and there is an emerging
correlation between stage of HIV and HAND.
Dr. Robert Heaton (UCSD) described two neuroAIDS
research projects in China; one in Yunnan (IV drug users)
and the other in Anhui (blood donors). In Anhui,
researchers enrolled 401 volunteers (203 HIV-1 seroposi-
tive, 198 uninfected) and will follow them through 12
annual checkups. At intake, the HIV+ volunteers were
mostly CDC stage A, with few co-morbidities other than
HCV, and 53% were already on ART. At 12 months, 95%
of the HIV+ volunteers returned for follow-up and
researchers found that 74% had suffered some neuro-
cognitive decline.
Dr. Vinayaka Prasad (Albert Einstein College of Medicine)
reported on a capacity-building program that provides
research training for neuroAIDS researchers from India,
Rwanda, and Bangladesh. Using the severe combined
immuno deficiency mouse HIVencephalitis model, research-
ers have established that—even when CNS viral loads are
similar—infection with HIV clade C causes milder neuropa-
thology and milder cognitive deficits than does infection with
HIV clade B. In addition, macrophages infected with clade C
recruit fewer monocytes, a subdued response that is mediated
by Tat and CCL2, and induce lower levels of chemokines and
inflammatory cytokines than clade B. Future research will
attempt to translate these findings into human populations,
looking at the incidence of dementia associated with
progressive HIV-1 infection in clade C or clade B populations
and determining the mechanism and viral determinants of
HAND and HAD, as well as host factors and possible targets
for therapeutics.
The International Neurological Study (NIMH-ACTG
5199): recent findings and challenges
Dr. Kevin Robertson (University of North Carolina at
Chapel Hill) reported on the status of this prospective
protocol, which is linked by co-enrollment to ACTG 5175.
It will follow 860 treatment-naive volunteers at 11 sites—
two each in Brazil, India, Malawi, and South Africa, and
one each in Thailand, Peru, and Zimbabwe—who will be
given three different ARV combinations and tested using
standardized neurocognitive and neuromotor tools. The
strengths of this design include consistent follow-up, high
retention rates, and shared infrastructure (the AIDS Clinical
Trials network). Challenges include language, culture, and
network issues, as well as great distances that complicate
supply, samples, and data transfer. Future studies may
include controls, additional clades and subtypes, and
additional treatment regimes.
In response to questions, Dr. Robertson added that
informed consent is a widespread and continuing problem.
Investigators want a uniform process for institutional
review board (IRB) approvals. He discussed the need for
the creation of central IRB organizations, which should be
part of the international infrastructure. Cultural differences
can be sogreat that US standards and procedures may well be
irrelevantinThailandandelsewhere.TheDivisionofAIDSor
DAIDS now has a central person for consent issues, and the
National Cancer Institute has regional IRBs, which are useful
backup for local groups. Other participants suggested that
investigators take advantage of the National Institute of
Allergy and Infectious Diseases (NIAID) Networks or similar
groups such as INSIGHT, START, ESPRIT, or CPCRA.
NIH-funded resources for domestic and international
neuroAIDS research
Opportunities for collaboration between NeuroAIDS
investigators and NIAID- or NICHD-funded projects
Dr. Robin Heubner (NIAID) described the Multicenter
AIDS Cohort Study (MACS), which has been enrolling
participants at four sites since 1984 and now stands at 7,000
homosexual and bisexual men: 2,500 of them in long-term
follow-up (1,200 HIV+, 1,300 uninfected), including 24%
African-American and 11% Latino. Semiannual visits
collect data on 8,500 variables, including confounders and
co-morbidities, and the MACS currently holds 1.2 million
aliquots of serum and CSF. Neuropsychological screening
includes psychosocial questions, standard verbal and motor
tests, and a trailmaking task and symbol digit test;
volunteers are referred for further testing as appropriate.
Investigators do not have to be part of MACS to make use
of this resource—they can apply for specimens and data
using a simple form, and the program seldom refuses such
requests. However, MACS does operate under the “dibs”
rule (first come, first served). Outside investigators do well
to collaborate with participating investigators.
Dr. James Becker (University of Pittsburgh Medical
School), a participating MACS investigator, reported that
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research careers. Admittedly, there is a survivor bias—these
data represent long-term non-progressors—but outside
investigators can obtain clean, case-controlled data on the
entire cohort or on subsets, such as stimulant users, without
having to do any recruiting themselves. He would like to
see MACS extend its data collection to include cerebro-
vascular disease subsequent to ART and imaging data to
differentiate between HAND and co-morbidities.
Dr. Gerald Sharp (NIAID) summarized the Women’s
Interagency HIV Study (WIHS), launched in 1993 by several
NIH institutes, which is currently following 2,500 women
who represent the epidemic in terms of race, ethnicity, drug
use, etc. This too is a large, well-characterized cohort with a
lotofspecimensthathasalreadybeenthesubjectof30funded
studies andhas the capacitytorapidlyaddress new avenues of
research.Agingandneurocognitivedisordersarenewareasof
emphasis, and investigators have recently added hearing and
balance tests to a battery that includes screening for trauma,
posttraumatic stress disorder, depression, and menopause.
Sharp added that the disconnect between the WIHS site from
the sites of HIV clinical care have made some of these
measures and outcomes unclear. Future research directions
will include a greater emphasis on the influence of behavioral
factors on disease progression and HIV management.
Dr. Rohan Hazra (National Institute of Child Health and
Human Development [NICHD]) described three pediatric
and adolescent HIV cohorts supported by NICHD: (1)
Pediatric HIV/AIDS Cohort Study (PHACS)—34 sites at
24 institutions in 20 US cities, following 400 HIV-1
volunteers and 150 controls with semiannual visits that
include behavioral and neurological screening; (2) NICHD
International Site Development Initiative (NISDI)—15 sites
in eight cities in four Latin American countries, currently
enrolling volunteers for two protocols that are similar to
PHACS; and (3) Adolescent Medicine Trials Network
(ATN) for HIV/AIDS Interventions—15 sites in the USA
that follow behavioral, microbicidal, prophylactic, thera-
peutic, and vaccine interventions in HIV-infected and HIV
at-risk adolescents age 12 through 24. In response to
questions, Dr. Hazra said that at present there is no single
catalog of cohorts and specimens (sera, cells, preservation
methods) that can be accessed through these networks but
that such a catalog would be a valuable resource.
National NeuroAIDS Tissue Consortium (NNTC): future
research directions and opportunities for research
collaborations with the neuroAIDS community
Dr. Benjamin Gelman (University of Texas) explained that
combination ART has improved the health and survival of
HIV patients, but neuroAIDS remains prevalent. The mission
of NNTC is to collect and distribute to the research
community critical biological specimens and biomedical data
from patients with HAND, peripheral neuropathy, and other
comorbid conditions. This means that it now constitutes a
unique, longitudinally characterized group of HIV-infected
individuals that is geographically and demographically
heterogeneous, includes a relatively old and sick population,
and provides a lot of data on complex neurological manifes-
tations. The NNTC cohort currently includes 2,262 volun-
teers, of whom 2,076 are HIV-1-seropositive and 622 are
currently active. Specimen collections include a wide range of
CNSandothertissues,including417HIV+brains.Volunteers
have also been characterized for prevalence of HAND and
peripheral neuropathy, psychiatric and substance abuse
disorders, and many histopathology diagnoses.
Shipments of NNTC specimens and data to investigators
rose from only 377 in 2002 to 2,427 in 2007, contributing
to 241 publications and 11 current grants, but in Gelman’s
opinion, this collection remains an underutilized resource.
NTCC is taking steps to standardize, harmonize, and
consolidate data management from contributing sites; and
it has plans to install new software tools that will make it
easier for investigators to obtain statistical analyses, as well
as raw data from the NTCC database. In the future, NTCC
brain samples should play a unique and valuable role in
comparing, correlating, and confirming the physical and
chemical changes that take place in HIV-associated disease
at the level of specific circuits and regions of the brain.
They will also allow investigators to compare neuropatho-
logical outcomes with specific therapies antemortem and to
disentangle the contributions of HIV and co-morbidities,
particularly HCV and drug abuse.
Despite the many opportunities offered by this resource,
limited financial and human resources mean that not all
avenues will be pursued. NNTC believes that the following
areas of research should be priorities:
& Include a greater portion of aged people, in order to
compare normal aging with neurodegenerative aging
& Integrate comorbidconditionsintothe neuroAIDS agenda
& Pay more attention to HAND of the “other type” (i.e.,
without HIV-encephalopathy)
& Use NNTC resources to establish and promulgate
standards of clinical relevance
& Use NNTC dorsal root ganglia collection to promote
study of peripheral neuropathy
& Elucidate the unique attributes of ethnic, linguistic, and
educational minorities with HIV
& Use NNTC brains, fluids, and tissues to study CNS
virology and HIV evolution in the context of ART
& Study the impact of genetic and epigenetic changes in
neuroAIDS
& Standardize, harmonize, and consolidate NNTC with
other neuroAIDS databases
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difficult to study AD and other non-HIV dementia in the
NNTC, but there is no evidence that they are more common
in HIV-1-seropositive patients. This finding is hardly
conclusive; however, since HIV autopsies are age 50–70,
they might miss subtle precursors of AD. There is a
common worry that HIV accelerates aging, but there is
reason to think that HAD would contribute to the clearing
of diffuse plaques, not their accumulation. Perhaps, it
would be possible to use NNTC samples to validate
markers of the early development of Alzheimer’s, but
perhaps NNTC research should instead focus on subcortical
dementia (like HAND, Parkinson’s and Huntington’s
disease) rather than cortical dementia such as Alzheimer’s.
NIMH centers program: potential role as a national resource
for neuroAIDS research
Dr. Ronald Swanstrom (University of North Carolina at
Chapel Hill) explained that the three NIMH-funded centers
of neuroAIDS research provide the infrastructure and
critical mass of expertise for synergistic approaches, using
inter- and multidisciplinary techniques, whose results truly
are greater than the sum of their parts.
Dr. Howard Fox (UNMC) described progress in devel-
oping biomarkers for HIV infection and neuropathological
sequelae.“Omics”technologies,inparticular,havefacilitated
rapid discovery and validation of biomarkers for HAND.
Justasgenomicshascontributedtoourunderstandingofviral
and host factors that affect the course of infection, tran-
scriptomics reveals that interferon-induced genes play
different roles in blood and brain and that osteopontin can
provide a valuable marker for HAND in the ART era,
although it is not diagnostic. Proteomics, likewise, has
revealed that HIVinfection causes multiple changes in blood
and CSF proteins preceding the onset of clinical CNS
disease. Metabolomics has led to the identification of several
low-molecular-weight metabolites that reflect biochemical
changes in the CNS following infection. Taken together,
these approaches may lead to fast, sensitive tests for
diagnosing and monitoring neuroAIDS.
Dr. Grant (UCSD) explained that UCSD’s HIV Neuro-
behavioral Research Center (HNRC) has five research cores
that provide resources and opportunities for startup research:
neuromedical, neurobehavioral, neuroimaging, neuro-
biology, and neurovirology. HNRC has recently added an
international core,which providestraining,technicalsupport,
and information exchange for foreign investigators, who
receive about $15,000 per year to produce preliminary data
and assistance in proposal design, and additional money to
actually apply for grants. This assistance has led to success
for seven different research projects with NIH funding
coming in the form of U13, R21, and R01 grants.
Dr. Justin McArthur (JHU) pointed out that, to date,
no therapies, diagnostics, or biomarkers for HAND have
entered clinical practice. Therapy in particular remains a
serious gap, since HAND remains prevalent even in the
ART era, and adherence is known to be a problem in
cognitively impaired patients. As a result, Hopkins has
established a therapeutics core to provide support for new
researchers, innovative studies, and collaborative
approaches. Its initial focus is on screening for neuro-
protective compounds, but it is also developing a clinical
cohort and protocols for clinical trials. There is also a
need for simple biomarkers (associative, correlative, or
predictive) that are cheap and simple enough to be rolled
out in low-resource nations. Plans to build a colony of
macaques, and perhaps develop transgenic animals, have
not yet been funded. Clearly, there is ample opportunity
for interactions and collaborations with other neuroAIDS
centers.
Therapeutics
NIMH Integrated Clinical–Preclinical Program (IPCP)
for novel neuroAIDS therapies
Dr. Steven D. Douglas (University of Pennsylvania School
of Medicine) described progress in developing an HIV
therapy based on antagonists to the neurokinin-1 receptor
(NK-1R). NK-1, also known as substance P, was the first
neuropeptide discovered (1931). It is widely distributed in
the central and peripheral nervous systems, where it
functions as a neurotransmitter, modulator of blood flow
and gastric activity, and—importantly—a potent mediator
of neuroimmunoregulation. An antagonist to NK-1R
(aprepitant) is standard therapy for chemotherapy-induced
nausea and vomiting and is also known to have antidepres-
sant activity. In addition, there is known to be a bidirectional
interaction between NK-1 and HIV. Serum substance P
levels rise significantly following HIVinfection, but NK-1R
agonists potently inhibit HIV replication in human macro-
phages, apparently by downregulating CCR5. Four projects
were launched to investigate these effects. Using R01 grants
from NIMH and tissue samples from NNTC, researchers
were able to confirm the in vitro and in vivo antiviral activity
of NK-1R. Further research has identified a new, tailless
variant that remains on the cell membrane, further inhibiting
the infectivity of HIV-1; this variant is the current target of
development. Researchers submitted their initial IND appli-
cation in July 2006; and after FDA comments, a revised IND
was approved in September 2006. The trial opened in
January 2007 and is currently accruing volunteers. Future
directions include further research on mechanisms, as well as
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in ART failure.
Dr. Harris Gelbard (University of Rochester Medical
Center) summarized a long-term collaboration between the
University of Rochester and UNMC, which first determined
that HIV Tat enhances the activity of glycogen synthase
kinase 3-beta (GSK-3β), an enzyme that plays a direct role
in neuronal apoptosis; identified a mixed lineage kinase
type 3 (MLK-3) as an alternative target of Tat; and
demonstrated that an inhibitor to MLK-3 can block the
toxic effect of Tat and extend the survival of rat and human
neurons in vitro. Ironically, this inhibitor (CEP1347) was
available from Cephalon Inc., which had developed it as a
treatment for Parkinson’s disease and did not see neuro-
AIDS as an important target. Researchers have partnered
with BioFocus DPI to further refine CEP1347 to arrive at
two lead compounds for preclinical testing. Meanwhile, a
related project has demonstrated that CEP1347 also blocks
that action of cPAF, another HIV toxin; this suggests a
second (neurovascular) locus of protection. Parallel studies
have shown that CEP1347 does not interfere with the
antiviral efficacy of NRTIs. Phase 1A pharmacokinetic
studies are currently underway.
Dr. Michael McGrath (University of California, San
Francisco) presented an update on his work in macrophage-
targeted drug development for neuroAIDS, in collaboration
with Boston College, the University of Hawaii, and
Pathological LLC. Discovered in 1898, mitoguazone, also
known as MGBG, had been investigated but abandoned as
an anticancer drug. However, it was also found to cause the
selective loss of CD16+ and CD16+ cells that contain HIV-1
DNA, specifically by blocking the synthesis of osteopontin
and Mac387 that are needed to transform a circulating
macrophage into a tissue (or CNS) macrophage. MGBG
appears to block CNS migration. Simian immunodeficiency
virus (SIV)-infected macaques treated with MGBG no
longer had infected macrophages in CNS, and the drug
appears to kill recent migrants rather than resident cells.
However, MGBG did not reduce plasma viremia, although it
does appear to shut down viral evolution. Current focus is on
the mechanism of operation and additional animal studies,
plus the development of biomarkers and clinical trial
protocols. In response to questions, Dr. McGrath said that
macrophages are a major site of viral evolution, if only
because macrophages do not die while replicating virus.
However, reservoirs of virus (and evolution) also exist in the
meninges, which are relatively understudied. MGBG
appears to be safe over the long term, as it has been through
26 cycles of biweekly treatment in patients with AIDS.
Dr. Mario Stevenson (University of Massachusetts
Medical Center) explained that because HIV-1 has such a
small genome, it must exploit host processes to replicate
and spread. However, several cellular restrictions (antago-
nists) resist this viral hijacking. For example, APOBEC3G
(A3G) restricts viral complementary DNA (cDNA) synthe-
sis and integrity, and tetherin restricts viral release from the
cell membrane. Consequently, much of HIV’s evolution
targets these cellular defenses by producing accessory
proteins such as Vif, which binds to A3G and induces its
degradation, and Vpu, which counteracts tetherin and
permits the release of new virus. Based on this knowledge,
investigators hypothesized that it should be possible to
identify small molecule antagonists of these and other viral
proteins, thereby restoring the protective function of
cellular restrictions. They began by screening a library of
30,000 small molecules for Vif inhibitors, leading to the
identification of two lead compounds (RN-18 and RN-19)
that inhibit Vif with the desired selectivity and effective-
ness. Mechanistic studies revealed that RN-18 increases
cellular A3G production in the presence of Vif and increases
A3G incorporation into virions, inducing hypermutation of
viral cDNA, confirming that the HIV-1 Vif-A3G axis is a
valid target for developing small molecule-based therapies
and/or enhancing innate immunity against viruses. The next
steps in developing such compounds will be to continue
animal studies up through rodents and NHPs and to search
for other HIV accessory proteins that might be similarly
targeted. Dr. Stevenson closed by noting evidence of fossil
viruses in the human genome that are sensitive to similar
restrictions; the challenge with HIV is to help the virus
become endogenous in less than 30,000 years.
Dr. Avindra Nath (JHU) identified three principal
challenges in drug development for HAD and HAND:
1. Identifying targets for treatment. Many different targets
have been identified, but most involve protecting the
neuron. Relatively few address earlier steps in the HAD
pathway, such as viral entry, replication, reservoirs, and
glial activation. It is hoped that NIMH’s Novel Neuro-
AIDS Therapies: Integrative Preclinical/Clinical Pro-
gram (IPCP) will help to expand the search by funding
research like the projects described above.
2. Developing therapeutic agents for those targets. Many
agents have been tested, most do not work, and none
work very well. Drug development requires a library of
candidate compounds and a series of increasingly
selective high-throughput screens. It has proven to be
very complicated (and very time-consuming) to screen
a novel library with a functional assay. Here again,
IPCP may prove helpful.
3. Collaborating with pharmaceutical companies. IPCP also
requires collaboration with industry and this introduces a
new set of challenges. Big Pharma has no interest in
neuroAIDS. Therefore, investigators must work with
small companies, but small companies have short life
spans and are subject to disruptive buyouts. This leaves
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ed scope and require investment, space, and other
resources. Universities can help by providing incubator
facilities to support and encourage these startups.
In response to questions, Dr. Nath added that intellectual
property can be a problem—generic drugs have no appeal
to any industrial partner, large or small; novel compounds
are far more attractive. However, the FDA “orphan drug”
program has shown that federal support can facilitate the
development of drugs and biological products for rare
diseases (read, “small markets”), and NIAID has aggres-
sively moved promising drugs into clinical trials. It would
be useful to bring these models to NIMH to encourage the
development of new therapies for neuroAIDS.
NINDS-funded Neurological Aids Research Consortium
(NARC)
Dr. David Clifford (Washington University School of
Medicine) reported that NARC was established in 1993
on the model of the NIAID-funded AIDS Clinical Trials
Group (ACTG). NARC serves as a catalyst for leadership
and new ideas in what has become a consortium of 30
research centers that conduct multicenter, controlled clinical
trials of neuroAIDS interventions, in addition to some
independent studies and several collaborations with indus-
try and international partners. NARC’s priorities are
reflected in its major research areas:
& Peripheral neuropathy—seven major projects in what is
the most common clinical complaint in neuroAIDS
& Neurocognitive disorders—eight studies, including
three international collaborations
& Opportunistic diseases—four studies of progressive
multifocal leukoencephalopathy and other opportunistic
diseases of neuroAIDS
& Domestic and international partnerships, including sites
in Uganda, Ethiopia, and Malaysia
NARC has always had a great interest in new drugs and
their effects on CNS and peripheral disorders. A new study
of Paxil (paroxetine) is currently under development, and
NARC will also be investigating the effects of multiple
drug regimes for peripheral neuropathy. In the future, there
are plans for more focused research on neuroregeneration
and pain management.
Priority-setting discussion session
Dr. Dianne Rausch (NIMH) thanked the presenters for their
review of the past and present of neuroAIDS research and
asked the participants to turn their attention to its future.
NIMH is now doing the strategic planning for initiatives
that will be launched in fiscal years 2010 and 2011, and it
wants to hear the ideas of this group, which includes most
of the senior leadership in the field. NeuroAIDS promises
to become an increasingly important topic, and the cohorts
and specimen collections described in this workshop
represent unique opportunities for collaboration. Funding
will remain tight; however, NIMH seeks advice on how to
use these resources most efficiently to address the most
important targets. With the November election, the nation
enters an era of change—political, professional, and
medical. How best can NIMH turn these changes into
opportunities for neuroAIDS research?
Clinical research
Dr. Francisco Gonzalez-Scarano (University of Pennsylvania)
suggested researchers look at Africa to find both the most
pressing questions and their likely answers. Recent evidence
points to microbial translocation as the cause of systemic
immune activation in chronic HIVinfection, and many of the
symptoms of neuroAIDS (as well as the opportunistic disease
of HIV) look very similar to autoimmune diseases. Yet all
current therapies against HIV target the virus (entry, integra-
tion, transcription) rather than its effects. In addition,
diagnosis for both HIV infection and CNS viremia typically
comes too late. Questions to consider include:
& Howdoweaddressthe problemsofthedevelopingworld?
& If there are CNS-specific treatments, how do we decide
who to treat and when?
& What is the influence of monocyte and T-cell activation
on HAD?
& Are minor cognitive problems worth treating or is their
genesis too confusing?
Dr. Fox (UNMC) observed that a great deal of work has
been done on HIV-related neurocognitive disorders and
dementia, but he asked whether this informs us about the
treatment of patients as HIV becomes a chronic disease (at
least in industrialized countries). Perhaps, we need a new
paradigm that focuses on lowering the virus count in the
brain and restoring a reasonable immune function. This new
paradigm raises new questions. What is the best model of the
chronic state under ART? How is CNS immunity different
from (and affected by) the rest of the body? What are the
patterns of CNS disease (e.g., cortical versus subcortical)? Is
HAND a different neuropathological entity from HIVE or
HAD? Biomarkers will be vital to the research that will
answer these questions, as are better in vitro and in vivo
models of neuroAIDS. Other important issues:
& Is neurogenesis impaired and does it matter?
& Neuroprotective responses and/or strategies
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& Immune reconstitution inflammatory syndrome and other
treatment effects
& Viral and host genetics
International neuroAIDS research
Dr. Eugene Major (NINDS) reported that NIH spends about
$365 million per year for AIDS research conducted in
international settings, out of a total AIDS budget of almost
$3billion.However,hefeltthatonlyasmallproportionofthe
NIH NeuroAIDS research budget is spent in international
settings. In addition, most of the money for neuroAIDS
currently goes to etiology and pathogenesis, with very little
going to areas such as vaccines and therapeutics. Neverthe-
less, there are several areas of basic research in which the
nervous system plays a key or unique role:
& Blood–brain barrier—virus, cell trafficking, drugs
& Brain as a reservoir for latency—where, how, and how
long
& Neurotrophins—protective and regenerative mechanisms
& Neural stem cells—targets for infection, response to
damage
& Neuronal pathology—transmitters, ion channels, plasticity
& NHP models—viral strains, clades, and pathogenesis
Many basic and clinical questions are difficult to address
in domestic settings, including natural history, comparative
populations, and viral pathology. International research is
best pursued through preexisting networks that have
cohorts, infrastructure, and community contacts. Better
coordination is needed in China and India, where local
networks are poorly linked. The time has also come for
better coordination across networks in such areas as
cohorts, sample inventories, and protocol design.
Dr. Grant (UCSD) presented a broader set of issues that
need to be addressed in international neuroAIDS research:
& What can international studies contribute to incre-
mental scientific knowledge about viral and host
genetics, cofactors and co-morbidities, and therapeutic
regimes?
& NeuroAIDS-relevant measures should be added to
ongoing international cohort studies, which can address
these questions at a low cost, but perhaps with less
sensitivity to early symptoms.
& More complicated questions (e.g., neuropathogenesis,
mechanisms) will require well-trained multidisciplinary
teams with appropriate infrastructure, such as well-
equipped regional centers of excellence.
& Greater international contributions will come only with
greater standardization of case ascertainment, diagnosis,
laboratory methods, and data management to ensure
global relevance, comparability, and generalizability.
& Finally, there is a great need to simplify and harmonize
the regulatory processes to improve the timeliness of
protocol review by US and foreign authorities; a
process that Grant characterized as “bureaucrolysis.”
Therapeutics
Dr. Douglas (University of Pennsylvania School of Medicine)
suggested six characteristics that should be met by candidate
neuroAIDS therapeutics and regimens: target entry, drug-
sparing, adjunct to ART, antiinflammatory, neuroprotection,
and reservoir depletion. In addition, a prompt way to move
candidates through the drug development pipeline needs to
be found. One way to do so would be with simulation
studies, which could then be confirmed by pharmacokinet-
ics. Finally,weneedtoagreeonalevelofacceptableresults—
would it be a 3-log reduction in copies per milliliter over
10 days? Even against that standard, however, there might be
some interest in a drug like Maraviroc (a CCR5 antagonist),
which achieves only a 0.5–1.0 log reduction, but nevertheless
is the first therapeutic that targets entry, rather than the virus
itself.
Dr. McArthur (JHU) suggested that there remains a need
for research on the impact of neuroAIDS and for better
biomarkers for diagnosis and treatment response. He also
posed a series of clinically relevant questions to be
addressed in the design of neuroAIDS therapeutic and
adjunctive trials:
& How reversible is HAND, and when should treatment
start?
& If virologic suppression is complete, will this protect
against HAND?
& What new targets of therapy are most likely to close the
treatment gap?
& What are the determinants of treatment response?
& How can we identify co-morbidities, especially aging
and depression?
& Can we improve outcome measures to reduce variability
and sample size?
Pediatric neuroAIDS
Dr. Leon Epstein (Northwestern University Feinberg
School of Medicine) observed that, similar to the general
AIDS community ignoring neuroAIDS, the neuroAIDS
community likewise ignores pediatrics. The biggest change
in pediatric neuroAIDS has come from ART, which reduces
mother-to-infant transmission—at least in the developed
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in our response to pediatric neuroAIDS:
& Are we applying the available drugs optimally?
& In particular, when should we start therapy, given that
both toxicity and pathogenesis may be different in a
developing brain?
& How can we improve the drug development pipeline,
which is too expensive (and thus too timid) to pursue
neuroAIDS therapeutics aggressively?
Discussion
During thediscussion thatfollowed,one ormoreparticipants
identified several important topics as deserving further
investigation. These topics are summarized below in no
particular order, other than the sequence in which they were
raised during the discussion.
Does neuroAIDS progress in patients who are virally
controlled? This begs the more basic question of whether
peripheral or CNS virus is the reservoir during latency. A
systematic study will be needed to answer these questions.
However, troubling data have emerged from the CHAR-
TER study suggesting that controlling the virus is not the
same as eliminating the virus (or its effects) and that
macrophages/microglia represent a major CNS reservoir of
virus. Elyse Singer, University of California, Los Angeles,
reported that she sees neurocognitive deficits in about half of
her AIDS patients and that it seems to progress even with
undetectable levels of CNS and plasma virus. However, there
are no clinical guidelines for the treatment of neuroAIDS, and
most clinicians do not even screen for it if they encounter
peripheralneuropathy.Ifneurologicaldiseasedoesprogressin
virally controlled patients, the patients need to be informed.
Unique opportunities for neuroAIDS research in large US
cities Immigration has created a single setting with small
numbers of all possible populations—Why not study
neuroAIDS in these populations in an industrialized
setting? However, it is likely that investigators will find
that the real problems in this group are not cognitive deficit,
but gross psychiatric disease, complicated by IV drugs and
other behavioral factors.
International research is vital There is no way to control
the epidemic without trained personnel who can transfer
existing knowledge as well as acquire new knowledge. In
addition, the interaction of HIVand opportunistic infections
cannot be properly studied in domestic settings. However,
President’s Emergency Plan for AIDS Relief (PEPFAR) has
not really helped research, even international research. In
general, NIH spends 10% of its AIDS budget on interna-
tional activities. Should NIMH ask for new money or
prioritize the available budget? What are the most important
questions for international settings? Progression under
ART? Migration of macrophages? Or the curious appear-
ance of strokes and atherosclerosis among young HIV-1
seropositive men in Africa, a phenomenon that may not be
unique to Africa?
Do more with available therapeutics Are there better ways
to use existing ART to target the CNS and improve their
effectiveness against neuroAIDS. Certainly, all new ARTand
adjuncts should be routinely screened for neuroAIDS indica-
tions. Some patients have a variety of cognitive and motor
impairments, each of which has its own treatment regimen,
some of which involve pretreatment with steroids. We need a
more comprehensive, neuroprotective therapy for neuroAIDS
that will preserve neurological function and quality of life.
NeuroAIDS is a bigger problem than we thought Current
estimates of the incidence of HAND put it at 30% of AIDS
patients, which would make it the third most common
dementia in the world. Good data are emerging from ACTG
5199, but a more definitive study with standardized data
will be needed to define global incidence.
Collect better data on neuroAIDS One participant suggested
that neurocognitive categories should be added to the data
collected by the International Epidemiologic Databases to
Evaluate AIDS. This would require standardized measures to
diagnose and quantify neurocognitive impacts. It would also
be expensive; and while NIMH would like to make this
change, it might be more effective to make better use of
existing resources.
Involve the broader community and broaden the research
focus NeuroAIDS does not just affect the patient; it also
affects their caregivers and medical personnel. However,
neurologists and psychiatrists are not dealing with neuro-
AIDS, despite its many commonalities with Alzheimer’s
and multiple sclerosis. There may be clues in the successful
treatments of those diseases. By the same token, how
can the study of neuroAIDS inform the study of other
neurodegenerative diseases? Will it be possible to develop
standardized measures, assays, and imaging protocols?
Patients do not die from neuroAIDS Instead, they die from
opportunistic infections (OIs), especially internationally,
often before they have time to become demented. In
addition, OIs add significantly to the cost of treating AIDS
patients. Ideally, we should treat HAND and neurological
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toxoplasmosis encephalitis, the most common neurological
condition in HIV-1-seropositive patients in the ART era.
Several therapies are available in the USA, at widely
varying prices; but cheaper alternatives will be needed to
address this problem in the rest of the world.
We may be seeing a paradigm shift in the study of neuro-
AIDS Past research has focused narrowly on the virus, and
as a result, all available therapeutics target the virus.
NeuroAIDS would now appear to be a broader and more
complex process of immune dysregulation that involves
multiple systems. As a result, neuroAIDS researchers will
need to think more globally, in terms of reservoirs, other
cell types, neurodevelopment, and other drug targets. To do
this, they will need to bring additional scientific disciplines
to bear on neuroAIDS and put together interdisciplinary
research teams.
Develop better animal models of neuroAIDS Several
participants suggested that current animal models do not
accurately portray the current, clinical experience of viral
control, and chronic inflammation under ART. In SIV, early
events determine the neurological outcome, but the virus is
in the brain early and death sometimes follows within
30 days. The endotoxemic mouse may be a better (or less
expensive) model of chronic CNS inflammation. There is a
special need for animal studies to determine when to initiate
neuroprotective therapy, as well as for vaccine studies, and
in a few years, there will be a demand for additional
animals to test the in vivo efficacy of the numerous HIV
protein antagonists that will emerge from current research.
Standardization will enhance collaboration NIH and others
have invested millions of dollars in developing extensive
data sets and specimen collections; but while the cohorts
must remain separate, there is no need for the data and
specimens to remain separate. NIMH should do more to
ensure that data collection produces a research set. It should
also support efforts to harmonize and standardize the
definitions, categories, measures, assays, and protocols that
are used by different collaborations; encourage those
collaborations to share data and compile catalogs of their
specimen collections; and to make these resources available
to outside investigators. One participant suggested that a
good initiative in this direction would be for NIMH,
NINDS, and NIDA to convene a consensus conference or
to sponsor a consensus paper to set out the components of a
standard neurological evaluation for HIV patients. Another
participant said that this would take 5 to 7 years to get into
the scientific literature and suggested that NIH could make
it so tomorrow, by merely promulgating the standard itself.
The NIH standards could take the form of a “tool box” that
identifies all of the validated tests that are available for
evaluating the cognitive, verbal, and motor abilities of
neuroAIDS patients.
Follow-up of well-characterized cohorts Uncertainty about
the progression of HAND during HAART can be addressed
through careful tracking of patient cohorts. Natural history
(ALLRT, CHAVI, CHARTER) and neuroprotective clinical
trial cohorts (ACTG) implement validated clinical, neuro-
psychologic, and virologic tests that are critical for
assessing long-term outcomes. Short-term studies (months)
are unlikely to yield definitive conclusions about the
effectiveness of neuroprotective strategies in a chronic
syndrome such as HAND. Long-term outcomes (years)
must be determined in such carefully characterized cohorts.
Involving the vaccine community in CNS studies Vaccine
testing in the macaque SIV models provides valuable
information about effectiveness of immune-mediated sys-
temic viral load suppression on immunopathogenesis and
survival. Similar CNS studies in vaccine cohorts are critical
to determine the neuroprotective potential of effective
vaccines. Macaque vaccine studies produce tissue speci-
mens and laboratory data that can strongly support
correlative and outcome-based studies of CNS pathogene-
sis. Systematic analyses of CNS tissues in these animals
should be aggressively pursued. The CHAVI study of
innate immunity markers (120 acute HIV infections/AHI) is
defining the kinetics of systemic elevations in acute-phase
proteins, cytokines, and chemokines during the earliest
stages of infection (transmission, viral eclipse phase). The
frequencies and function of peripheral DC, NK, and NKT
cells and the kinetics of antibody production are also being
examined. These early events could influence CNS inva-
sion, neuroimmune responses, and cognitive outcomes.
What early events influence CNS outcomes? This is among
the most difficult questions to answer and it requires
longitudinal analyses of recent seroconverters (CHAVI).
Functional brain imaging is critical for defining early brain
responses to systemic and CNS infection because it is the
only method capable of analyzing brain metabolism in real
time. However, the necessary technology for such studies is
not easily transferable in limited resource settings. Acute
HIV infection serological markers of innate immunity (IB)
should be examined as associative and predictive markers
for neuropathogenesis.
Host responses in the CNS Along with analysis of CNS
neurochemical responses by functional imaging, cerebrospi-
nal fluid sampling and analysis are also essential. Long-term
follow-up of carefully characterized cohorts (e.g., CHAVI
seroconverters) is essential; short-term cohort studies repre-
296 J Neuroimmune Pharmacol (2009) 4:283–297sent a relatively inefficient use of resources. This will
determine whether targeted neuroprotection can or should
be applied in chronically infected individuals.
When should treatment be initiated? Current criteria for
initiation of ART do not consider CNS outcomes as a
benchmark of efficacy. Establishing CNS-based criteria for
initiation of therapy should be the ultimate goal of neuro-
protection strategies. This applies to ARTas well as candidate
adjunctive neuroprotective drugs as they are developed.
Determining neurological outcomes in acute seroconverters
(ART treated and untreated) is the critical first step.
Opportunistic infections—optimal and cost-effective treat-
ment The diagnostic criteria will depend on standard
laboratory diagnostic tests and cost-effective brain imaging.
Preliminary studies support OIs as significant contributors
to the morbidity of AIDS in underdeveloped countries. The
first priority should be determination of the prevalence of
CNS OIs (TB, toxoplasmosis, crytptococcus).
Other complications (i.e., vascular) The effects of HIVand
ART accelerate the risk of cardiovascular disease, but the
risk of cerebrovascular disease (CVD) and its complications
is undefined. Recent studies within the USA suggest an
increased risk of CVD, and investigating this risk in
patients in underdeveloped countries requires technology
transfer and infrastructure development.
Influence of cellular entry on the development of CNS
infection The SIV macaque models most closely mimic
HIV infection in humans. Both acute and chronic CNS
pathogenesis models are useful, and emphasis should be
placed on developing antiretroviral drug treatment para-
digms that mimic ART regimens and that alter disease
course. Defining sources and adequate supplies of drugs is
a priority. Other relevant models should be explored but
realistically, to date none have fully modeled the steps from
HIV neuroinvasion through neurodegeneration.
Concluding remarks
The importance of neuroAIDS remains significant to the
HIV/AIDS problem. This series of discussions and priority
sharing have served to bridge needed research to outline a
plan for growth and development of the field and to tackle
critical problems overall. These priorities and ideas provide
a template for future growth of the field and its long-term
impact.
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